VANI — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-13

• Our main priority is the further development of our miniature, ultra long-acting drug implant candidate programs. In parallel, our management team remains committed to enabling further development of Cortigent’s pioneering neurostimulation systems from legacy company Second Sight which are aimed at …

• On May 22, 2026, the Company entered into an agreement with Novo Nordisk ("Novo") that enables Novo to conduct a non-exclusive internal evaluation of NPM-139 semaglutide implants prepared by Vivani. The agreement was publicly disclosed on July 7, 2026. There are no exclusivity provisions for NPM-139…

• On July 29, 2026, the Company treated the first patient in the SLIM-1 trial of NPM-139 (semaglutide) implant and subsequently completed dosing all patients in the study one week later. We currently anticipate topline data for the trial will be available in November, 2026.

• We have experienced recurring operating losses and negative operating cash flows since inception and we expect to continue to incur operating losses and negative operating cash flows for the foreseeable future. To date, we have financed our working capital requirements through the recurring sale of …

• There were no accounting standards adopted during the six months ended June 30, 2026, that had a material effect on the Company’s condensed consolidated financial statements.

Text removed vs the prior filing · source: 10-Q · 2026-05-13

• We have experienced recurring operating losses and negative operating cash flows since inception and we expect to continue to incur operating losses and negative operating cash flows for the foreseeable future. To date, we have financed our working capital requirements through the recurring sale of …

• We estimate that currently available cash will provide sufficient funds to enable us to meet our planned obligations into mid-2027. Our ability to continue as a going concern is dependent on our ability to raise additional capital, however, there can be no assurances that we will be able to do so.

• A description of recently adopted accounting standards disclosed in Note 2 to our interim unaudited condensed consolidated financial statements included in Item 1 of this Form 10-Q.

• Comparison of the Three Months Ended March 31, 2026 and 2025

• General and administrative expense, net of grants. General and administrative expense, net of grants, during the three months ended March 31, 2026 was $2.4 million, compared to $2.3 million during the three months ended March 31, 2025. The increase of $0.1 million, or 4%, was primarily attributable …